Physician profile
Keith A Scott
NPI 1740280718
$5,337.71
in general payments reported to CMS, 2019-2025
50 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $709 · 2021: $741 · 2022: $823 · 2023: $973 · 2024: $983 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,452.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $577.66 | 2019-2025 | Otezla, Repatha, Evenity |
| Abbvie INC. | $522.30 | 2021-2025 | Vraylar, Ubrelvy |
| Lundbeck LLC | $329.62 | 2022-2025 | Vyepti, Rexulti |
| Otsuka America Pharmaceutical, INC. | $328.67 | 2020-2025 | Rexulti, Nuedexta |
| Novartis Pharmaceuticals Corporation | $315.83 | 2019-2025 | |
| Abbott Laboratories | $286.14 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $255.17 | 2019-2024 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $225.23 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $193.98 | 2019-2024 | Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $186.26 | 2021-2025 | Hyqvia, Trintellix |
| Glaxosmithkline, LLC. | $156.15 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $152.10 | 2021-2024 | Jardiance, Mounjaro |
| Dexcom, INC. | $144.63 | 2021-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $133.69 | 2020-2023 | |
| Daiichi Sankyo INC. | $121.54 | 2020-2025 | Injectafer |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.